Insulin therapy in diabetes and cancer risk: Current understanding and implications for future study

Advances in Therapy

Volumn 28, Issue SUPPL. 5, 2011, Pages 1-18

  Gough, Stephen C L ^a   Belda Iniesta, Cristóbal ^b   Poole, Christopher ^c   Weber, Matthias ^d   Russell Jones, David ^e   Hansen, Bo Falck ^f   Mannucci, Edoardo ^g   Tuomilehto, Jaakko ^h  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^e UNIVERSITY OF SURREY   (United Kingdom)

^f NOVO NORDISK A S   (Denmark)

^g Careggi Teaching Hospital   (Italy)

^h UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Cancer; Detemir; Diabetes; Glargine; Insulin; Insulin receptor; Insulin like growth factor; Mitogenicity

Indexed keywords

INSULIN; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN X10; ISOPHANE INSULIN; METFORMIN; SHORT ACTING DRUG; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SULFONYLUREA; UNCLASSIFIED DRUG;

ACROMEGALY; BINDING AFFINITY; BREAST CANCER; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENESIS; COLORECTAL CANCER; CONFERENCE PAPER; DIABETES MELLITUS; DOSE RESPONSE; DRUG MEGADOSE; DRUG POTENCY; DRUG RECEPTOR BINDING; FINLAND; HOSPITAL DISCHARGE; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPOGLYCEMIA; HYPOGONADISM; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN TREATMENT; INSULINEMIA; ITALY; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MITOGENESIS; MITOGENICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS CANCER; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION;

DIABETES MELLITUS; EUROPE; HUMANS; INSULIN; NEOPLASMS;

EID: 84860388926     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-011-0047-8     Document Type: Conference Paper

References (79)

1. Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009;52:1732-1744.
2. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52:1766-1777.
3. Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdó ttir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia. 2009;52:1745-1754.
4. Colhoun HM; SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia. 2009;52:1755-1765.
5. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004;159:1160-1167. (Pubitemid 38747263)
6. Ogunleye AA, Ogston SA, Morris AD, Evans JM. A cohort study of the risk of cancer associated with type 2 diabetes. Br J Cancer. 2009;101:1199-1201.
7. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569-578. (Pubitemid 351232031)
8. Micic D, Cvijovic G, Trajkovic V, Duntas LH, Polovina S. Metformin: its emerging role in oncology. Hormones (Athens). 2011;10:5-15.
9. Kourelis TV, Siegel RD. Metformin and cancer: new applications for an old drug. Med Oncol. 2011. In press.
10. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006;29:254-258. (Pubitemid 44106500)
11. Hassan MM, Curley SA, Li D, et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer. 2010;116:1938-1946.
12. Pocock SJ, Smeeth L. Insulin glargine and malignancy: an unwarranted alarm. Lancet. 2009;374:511-513.
13. European Medicines Agency. European Medicines Agency 2011 Priorities for Drug Safety Research: insulin/insulin analogues and cancer EMA/425284/2010. http://www.ema.europa.eu/ docs/en-GB/document-library/Other/2010/07/ WC500094265.pdf. Accessed May 5, 2011.
14. Mannucci E, Monami M, Balzi D, et al. Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care. 2010;33:1997-2003.
15. Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR, Meier CR. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care. 2010;33:1304-1308.
16. Donadon V, Balbi M, Valent F, Avogaro A. Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma. World J Gastroenterol. 2010;16:3025-3032.
17. Zhou XH, Qiao Q, Zethelius B, et al; DECODE Study Group. Diabetes, prediabetes and cancer mortality. Diabetologia. 2010;53:1867-1876.
18. Wallner LP, Morgenstern H, McGree ME, et al. The effects of type 2 diabetes and hypertension on changes in serum prostate specific antigen levels: results from the Olmsted County study. Urology. 2011;77:137-141.
19. Turner EL, Lane JA, Donovan JL, et al. Association of diabetes mellitus with prostate cancer: nested case-control study (prostate testing for cancer and treatment study). Int J Cancer. 2011;128:440-446.
20. Bartke A. Minireview: role of the growth hormone/ insulin-like growth factor system in mammalian aging. Endocrinology. 2005;146:3718-3723. (Pubitemid 41175738)
21. Cohen HY, Miller C, Bitterman KJ, et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science. 2004;305:390-392. (Pubitemid 38938153)
22. Carter CS, Ramsey MM, Sonntag WE. A critical analysis of the role of growth hormone and IGF-1 in aging and lifespan. Trends Genet. 2002;18:295-301. (Pubitemid 34607119)
23. Kenyon C. The plasticity of aging: insights from long-lived mutants. Cell. 2005;120:449-460. (Pubitemid 40269760)
24. Suh Y, Atzmon G, Cho MO, et al. Functionally significant insulin-like growth factor I receptor mutations in centenarians. Proc Natl Acad Sci USA. 2008;105:3438-3442. (Pubitemid 351723571)
25. Renehan AG, Harvie M, Howell A. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. Endocr Relat Cancer. 2006;13:273-278. (Pubitemid 43886658)
26. Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGFbinding protein-3. J Natl Cancer Inst. 1999;91:620-625. (Pubitemid 29194048)
27. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998;351:1393-1396. (Pubitemid 28209997)
28. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 1998;279:563-566. (Pubitemid 28067285)
29. Jogie-Brahim S, Feldman D, Oh Y. Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev. 2009;30:417-437.
30. Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United KingdomAcromegaly Study Group. J Clin Endocrinol Metab. 1998;83:2730-2734. (Pubitemid 28493768)
31. Weber MM, Fottner C, Liu SB, Jung MC, Engelhardt D, Baretton GB. Overexpression of the insulinlike growth factor I receptor in human colon carcinomas. Cancer. 2002;95:2086-2095. (Pubitemid 35253369)
32. Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA. 1993;90:11217-11221. (Pubitemid 23354400)
33. Kaleko M, Rutter WJ, Miller AD. Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol Cell Biol. 1990;10:464-473.
34. Gualberto A, Pollak M. Emerging role of insulinlike growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene. 2009;28:3009-3021.
35. Law JH, Habibi G, Hu K, et al. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res. 2008;68:10238-10246.
36. Bullough WS. A study of the hormonal relations of epidermal mitotic activity in vitro. II. Insulin and pituitary growth hormone. Exp Cell Res. 1954;7:186-196.
37. Katayama H. Studies on the mitosis of mouse ear epidermis in vitro. I. effect of insulin pretreatment on epidermal mitotic activity in vitro. Annot Zool Jpn. 1957;30:71-76.
38. Draznin B. Mitogenic action of insulin: friend, foe or 'frenemy'? Diabetologia. 2010;53:229-233.
39. Osborne CK, Bolan G, Monaco ME, Lippman ME. Hormone responsive human breast cancer in longterm tissue culture: effect of insulin. Proc Natl Acad Sci USA. 1976;73:4536-4540. (Pubitemid 8013935)
40. Gupta K, Krishnaswamy G, Karnad A, Peiris AN. Insulin: a novel factor in carcinogenesis. Am J Med Sci. 2002;323:140-145.
41. Holly JM, Perks CM. Cancer as an endocrine problem. Best Pract Res Clin Endocrinol Metab. 2008;22:539-550.
42. Rincon M, Rudin E, Barzilai N. The insulin/IGF-1 signaling in mammals and its relevance to human longevity. Exp Gerontol. 2005;40:873-877. (Pubitemid 41540436)
43. Ibanez de Caceres I, Cortes-Sempere M, Moratilla C, et al. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer. Oncogene. 2010;29:1681-1690.
44. Dziadziuszko R, Merrick DT, Witta SE, et al. Insulin- like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol. 2010;28:2174-2180.
45. Rajski M, Zanetti-Dällenbach R, Vogel B, Herrmann R, Rochlitz C, Buess M. IGF-I induced genes in stromal fibroblasts predict the clinical outcome of breast and lung cancer patients. BMC Med. 2010;8:1.
46. Turner BC, Haffty BG, Narayanan L, et al. Insulin- like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res. 1997;57:3079-3083. (Pubitemid 27351714)
47. Yu D, Watanabe H, Shibuya H, Miura M. Redundancy of radioresistant signaling pathways originating from insulin-like growth factor I receptor. J Biol Chem. 2003;278:6702-6709. (Pubitemid 36800657)
48. Dunn SE, Hardman RA, Kari FW, Barrett JC. Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res. 1997;57:2687-2693. (Pubitemid 27283781)
49. Buck E, Eyzaguirre A, Rosenfeld-Franklin M, et al. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res. 2008;68:8322-8332.
50. Guix M, Faber AC, Wang SE, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest. 2008;118:2609-2619. (Pubitemid 351949788)
51. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer. 2004;4:806-813. (Pubitemid 39331152)
52. Agin A, Jeandidier N, Gasser F, Grucker D, Sapin R. Glargine blood biotransformation: in vitro appraisal with human insulin immunoassay. Diabetes Metab. 2007;33:205-212. (Pubitemid 46863409)
53. Mayer D, Chantelau E. Treatment with insulin glargine (Lantus) increases the proliferative potency of the serum of patients with type-1diabetes: a pilot study on MCF-7 breast cancer cells. Arch Physiol Biochem. 2010;116:73-78.
54. Carroll RJ, Hammer RE, Chan SJ, Swift HH, Rubenstein AH, Steiner DF. A mutant human proinsulin is secreted from islets of Langerhans in increased amounts via an unregulated pathway. Proc Natl Acad Sci USA. 1988;85:8943-8947. (Pubitemid 19001821)
55. Gross DJ, Halban PA, Kahn CR, Weir GC, Villa- Komaroff L. Partial diversion of a mutant proinsulin (B10 aspartic acid) from the regulated to the constitutive secretory pathway in transfected AtT-20 cells. Proc Natl Acad Sci U S A. 1989;86:4107-4111. (Pubitemid 19154745)
56. Nielsen FS, Jørgensen LN, Ipsen M, Voldsgaard AI, Parving HH. Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen. Diabetologia. 1995;38:592-598.
57. Drejer K. The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. Diabetes Metab Rev. 1992;8:259-285.
58. Hansen BF, Danielsen GM, Drejer K, et al. Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem J. 1996;315(Pt 1):271-279. (Pubitemid 26113562)
59. Kurtzhals P, Schäffer L, Sørensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. 2000;49:999-1005. (Pubitemid 30349423)
60. Bornfeldt KE, Gidlöf RA, Wasteson A, Lake M, kottner A, Arnqvist HJ. Binding and biological effects of insulin, insulin analogues and insulinlike rowth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities. Diabetologia. 1991;34:307-313.
61. Milazzo G, Sciacca L, Papa V, Goldfine ID, Vigneri R. ASPB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: evidence for enhanced interactions with the insulin-like growth factor-I receptor. Mol Carcinog. 1997;18:19-25. (Pubitemid 27107371)
62. Drejer K, Kruse V, Larsen UD, Hougaard P, Bjørn S, Gammeltoft S. Receptor binding and tyrosine kinase activation by insulin analogues with extreme affinities studied in human hepatoma HepG2 cells. Diabetes. 1991;40:1488-1495.
63. Hamel FG, Siford GL, Fawcett J, Chance RE, Frank BH, Duckworth WC. Differences in the cellularprocessing of AspB10 human insulin compared with human insulin and LysB28ProB29 human insulin. Metabolism. 1999;48:611-617. (Pubitemid 29230522)
64. Kohn WD, Micanovic R, Myers SL, et al. pIshifted insulin analogs with extended in vivo time action and favorable receptor selectivity. Peptides. 2007;28:935-948. (Pubitemid 46349342)
65. Eckardt K, May C, Koenen M, Eckel J. IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts. Diabetologia. 2007;50:2534-2543. (Pubitemid 350060636)
66. Home PD, Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia. 2009;52:2499-2506.
67. Dejgaard A, Lynggaard H, Råstam J, Krogsgaard Thomsen M. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. Diabetologia. 2009;52:2507-2512.
68. Origin Trial Investigators, Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J. 2008;155:26-32.
69. Pollak M, Russell-Jones D. Insulin analogues and cancer risk: cause for concern or cause célébre? Int J Clin Pract. 2010;64:628-636.
70. Shukla A, Grisouard J, Ehemann V, Hermani A, Enzmann H, Mayer D. Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr Relat Cancer. 2009;16:429-441.
71. Sciacca L, Cassarino MF, Genua M, et al. Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia. 2010;53:1743-1753.
72. Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H. Insulin analogues display IGF-1-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev. 2009;25:41-49.
73. Yehezkel E, Weinstein D, Simon M, Sarfstein R, Laron Z, Werner H. Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor. Diabetologia. 2010;53:2667-2675.
74. Staiger K, Staiger H, Schweitzer MA, et al. Insulin and its analogue glargine do not affect viability and proliferation of human coronary artery endothelial and smooth muscle cells. Diabetologia. 2005;48:1898-1905. (Pubitemid 41317846)
75. Liefvendahl E, Arnqvist HJ. Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-1. Horm Metab Res. 2008;40:369-374. (Pubitemid 351967126)
76. Sommerfeld MR, Müller G, Tschank G, et al. In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. PLoS One. 2010;5:e9540.
77. Varewijck AJ, Goudzwaard JA, Brugts MP, Lamberts SW, Hofland LJ, Janssen JA. Insulin glargine is more potent in activating the human IGF-1 receptor than human insulin and insulin detemir. Growth Horm IGF Res. 2010;20:427-431.
78. Hansen BF, Stidsen CE, Glendorf T, Lundby A, Hegelund AC, Bonnesen C. Safety analysis of basal insulins: mitogenic potency and receptor binding. Diabet Med. 2010;27(Suppl. 1):Poster 95.
79. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin receptor isoforms and insulin receptor/insulinlike growth factor receptor hybrids in physiology and disease. Endocr Rev. 2009;30:586-623.